Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) are an established treatment for non‐small cell lung cancer (NSCLC) that have demonstrated durable clinical benefits (DCBs). Previous studies have suggested NY‐ESO‐1 and LAG‐3 to be surrogate markers of ICI responses in NSCLC; therefore, we explored th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Eun Hee, Jang, Hee Ryeong, Kim, Se Hyun, Suh, Koung Jin, Kim, Yu Jung, Lee, Ju‐Hyun, Chung, Jin‐Haeng, Kim, Miso, Keam, Bhumsuk, Kim, Tae Min, Kim, Dong‐Wan, Heo, Dae Seog, Lee, Jong Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919166/
https://www.ncbi.nlm.nih.gov/pubmed/33458968
http://dx.doi.org/10.1111/1759-7714.13834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919166/
https://www.ncbi.nlm.nih.gov/pubmed/33458968
http://dx.doi.org/10.1111/1759-7714.13834

Ejemplares similares